alisporivir profile

alisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11513676
CHEMBL ID	1651956
CHEBI ID	149837
SCHEMBL ID	6850787
MeSH ID	M0483496

Synonym
debio 025
deb025
debio-025
alisporivir
unil-025
deb-025
CHEBI:149837
CHEMBL1651956 ,
deb 025
(d-meala)3-(etval)4-csa
unil 025
bdbm50339127
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-((1r,2r,e)-1-hydroxy-2-methylhex-4-enyl)-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-((1r,2r)-1-hydroxy-2-methylhex-4-enyl)-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26
alisporivir (usan)
254435-95-5
D10087
meala(3)etval(4)-cyclosporin
unil025
unii-vbp9099aa6
alisporivir [usan:inn]
cyclo(l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl-(2s,3r,4r,6e)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl-(2s)-2-aminobutanoyl-n-methyl-d-alanyl-n-ethyl-l-valyl-l-valyl-n-methyl-l-leucyl)
vbp9099aa6 ,
debio025
alisporivir [who-dd]
alisporivir [inn]
alisporivir [usan]
SCHEMBL6850787
CS-7501
HY-12559
DB12139
Q4727236
MS-32057
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-((1r,2r,e)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tris(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5
DTXSID401027752
debio-025;deb-025
AKOS040741084

Excerpt	Reference	Relevance
"Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties."	( Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Ahmed-Belkacem, A; Ahnou, N; Berry, F; Brillet, R; Bruscella, P; Fourati, S; Hamadat, S; Morin-Dewaele, M; Nevers, Q; Pawlotsky, JM; Softic, L, 2020)	1.52
"Alisporivir (ALV) is an 11-amino-acid hydrophobic cyclic peptide with N-methyl-D-alanine and N-ethyl-L-valine (NEV) residues at positions 3 and 4, respectively. "	( X-ray structure of alisporivir in complex with cyclophilin A at 1.5 Å resolution. Bouckaert, J; Dujardin, M; Hanoulle, X; Rucktooa, P, 2018)	2.25
"Alisporivir (ALV) is a cyclophilin inhibitor with pan-genotypic activity against hepatitis C virus (HCV). "	( Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Guedj, J; Kern, S; Levi, M; Li, B; Naoumov, NV; Perelson, AS; Yu, J, 2014)	2.09
"Alisporivir is a novel cyclophilin-binding molecule with potent anti-hepatitis C virus (HCV) activity. "	( Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir. Alexander, N; Barve, A; Einolf, H; Gu, H; Hanna, I; He, H; Heimbach, T; Ke, J; Mangold, JB; Sunkara, G; Wang, L; Xia, B; Zhang, T, 2014)	2.06
"Alisporivir is a cyclophilin inhibitor with demonstrated in vitro and in vivo activity against hepatitis C virus (HCV). "	( A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response. Guedj, J; Levi, M; Mentré, F; Nguyen, TH; Yu, J, 2014)	2.09
"Alisporivir (ALV) is an oral, investigational host-targeting agent, with pangenotypic activity against hepatitis C virus (HCV). "	( Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. Alberti, A; Brass, C; Buti, M; Calistru, P; Chuang, WL; Davis, GL; Flisiak, R; Goeser, T; Horban, A; Kao, JH; Mazzella, G; Orsenigo, R; Pol, S; Rasenack, J; Streinu-Cercel, A; Tabak, F, 2015)	3.3
"Alisporivir is a cyclophilin inhibitor with pan-genotypic anti-hepatitis C virus (HCV) activity and a high barrier to viral resistance. "	( Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Avila, C; Chuang, WL; Flisiak, R; Foster, GR; Hézode, C; Li, B; Naoumov, NV; Pawlotsky, JM; Peng, CY; Piratvisuth, T; Rasenack, J; Sarin, SK; Shah, S; Wedemeyer, H; Wong, KA; Zhang, W, 2015)	3.3
"Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance."	( Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Abdurakhmanov, D; Bao, W; Brass, C; Buggisch, P; Calistru, P; Flisiak, R; Gould, M; Griffel, LH; Heo, J; Hsu, SJ; Makara, M; Mazur, W; Mazzella, G; Merz, M; Mutimer, D; Naoumov, NV; Nault, B; Samuel, D; Stanciu, C; Thongsawat, S; Van Kính, N; Vierling, JM; Zeuzem, S, 2015)	2.16
"Alisporivir (Debio 025) is a potent pan-genotypic host-targeting antiviral agent, acting on cyclophilin A, which is necessary for HCV replication."	( HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial. Crabbé, R; Cuypers, L; Kerremans, L; Libin, P; Snoeck, J; Van Dooren, S; Vandamme, AM; Vuagniaux, G, 2016)	1.38
"Alisporivir (Debio-025) is an analogue of cyclosporine A and represents the prototype of a new class of non-immunosuppressive cyclophilin inhibitors. "	( The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Capitanio, N; D'Aprile, A; Gavillet, B; Moradpour, D; Piccoli, C; Quarato, G; Vuagniaux, G, 2012)	2.12

Excerpt	Reference	Relevance
"Alisporivir has an excellent pharmacokinetic and safety profile."	( Profile of alisporivir and its potential in the treatment of hepatitis C. Gallay, PA; Lin, K, 2013)	1.5

Excerpt	Reference	Relevance
"Alisporivir pretreatment stimulated antigen presentation by hepatoma target cells, leading to enhancement of antigen-specific CD8(+) T cell activation by 40%."	( The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cell activation. Esser-Nobis, K; Lohmann, V; Neumann-Haefelin, C; Nitschke, K; Schmidt, J; Thimme, R, 2016)	1.46
"Treatment with alisporivir, but not with cyclosporin A, led to a substantial recovery of respiratory function matching improved muscle ultrastructure and survival of sapje zebrafish, a severe model of DMD where muscle defects are close to those of DMD patients."	( Alisporivir rescues defective mitochondrial respiration in Duchenne muscular dystrophy. Argenton, F; Bernardi, P; Menazza, S; Merlini, L; Petronilli, V; Sabatelli, P; Schiavone, M; Zulian, A, 2017)	2.24

Excerpt	Reference	Relevance
" The aim of the current work was to develop a novel physiologically based pharmacokinetic (PBPK) model to quantitatively assess the magnitude of CYP3A4 mediated drug-drug interactions with alisporivir as the substrate or victim drug."	( Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir. Alexander, N; Barve, A; Einolf, H; Gu, H; Hanna, I; He, H; Heimbach, T; Ke, J; Mangold, JB; Sunkara, G; Wang, L; Xia, B; Zhang, T, 2014)	0.81
" Co-administration with ketoconazole (a strong CYP3A4 inhibitor) increased the Cmax , AUC and terminal elimination half-life of alisporivir by approximately two-, eight- ,and threefold, respectively."	( The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans. Barve, A; Crabbe, R; Dabovic, K; Dole, K; Grosgurin, P; Ke, J; Kovacs, SJ; Menetrey, A; Nicolas-Métral, V; Praestgaard, J; Stein, D; Sunkara, G; Zhang, J, 2015)	0.85

Excerpt	Reference	Relevance
"6 log(10) units was obtained in phase II studies when Debio 025 was combined with interferon (R."	( Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G, 2009)	0.35
"These results confirm that Debio 025 has a potent activity and an additive effect on HCV RNA reduction in genotype 1 and 4 patients at 600 and 1,000 mg/day when combined with PEG IFN-alpha2a."	( The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Crabbé, R; Feinman, SV; Flisiak, R; Grosgurin, P; Heathcote, JE; Horban, A; Jablkowski, M; Kryczka, W; Liz, JS; Mazzella, G; Nicolas-Métral, V; Pawlowska, M; Porchet, H; Scalfaro, P; Vandelli, C, 2009)	0.35
" The aim of the current work was to develop a novel physiologically based pharmacokinetic (PBPK) model to quantitatively assess the magnitude of CYP3A4 mediated drug-drug interactions with alisporivir as the substrate or victim drug."	( Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir. Alexander, N; Barve, A; Einolf, H; Gu, H; Hanna, I; He, H; Heimbach, T; Ke, J; Mangold, JB; Sunkara, G; Wang, L; Xia, B; Zhang, T, 2014)	0.81
" We estimated the antiviral effectiveness of alisporivir alone or in combination with pegylated interferon (peg-IFN) in 88 patients infected with different HCV genotypes treated for 4 weeks."	( A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response. Guedj, J; Levi, M; Mentré, F; Nguyen, TH; Yu, J, 2014)	0.9

Excerpt	Relevance	Reference
" The treatment of target cells with agents that disrupt CypA-CA interactions often produced biphasic dose-response curves in which viral infectivity first increased and subsequently decreased as a function of the dose used."	( Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Clavel, F; Dam, E; Hance, AJ; Lecossier, D; Matsuoka, S, 2009)	0.35
" We simulated virologic responses with other alisporivir dosing regimens in HCV genotype 2/3 patients using the model."	( A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response. Guedj, J; Levi, M; Mentré, F; Nguyen, TH; Yu, J, 2014)	0.9

Role	Description
anticoronaviral agent	Any antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
homodetic cyclic peptide	A homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	0.1100	0.1100	7.1903	10.0000	AID1168844
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	0.5900	0.0002	2.3185	10.0000	AID1168846
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	Ki	0.0003	0.0003	0.0473	0.2310	AID581778
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	18.0000	2.4100	6.3433	10.0000	AID1168843
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	IC50 (µMol)	0.2200	0.1047	2.7195	7.0795	AID1168842
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	2.5000	0.0040	1.9666	10.0000	AID1168845
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	IC50 (µMol)	0.4900	0.0500	2.3797	9.7000	AID1168826; AID1168841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)	Kd	0.0010	0.0010	0.0053	0.0098	AID1168835
Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)	Kd	0.0010	0.0010	0.0028	0.0042	AID1168836
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	Kd	0.0066	0.0022	0.4297	6.4200	AID1168824; AID719606
Nonstructural protein 5A		EC50 (µMol)	0.0158	0.0000	0.1375	8.1000	AID1714205
RNA-directed RNA polymerase		EC50 (µMol)	0.0158	0.0018	0.2348	2.8000	AID1714203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
chaperone-mediated protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
regulation of post-translational protein modification	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
neutrophil chemotaxis	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation of multicellular organism growth	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation by host of viral process	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation by host of viral genome replication	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein stabilization	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
bone development	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
chaperone-mediated protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
response to ischemia	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
apoptotic mitochondrial changes	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
regulation of proton-transporting ATPase activity, rotational mechanism	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of ATP-dependent activity	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
regulation of mitochondrial membrane permeability	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial depolarization	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
necroptotic process	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cellular response to hydrogen peroxide	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cellular response to arsenic-containing substance	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cellular response to calcium ion	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of oxidative phosphorylation	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
skeletal muscle fiber differentiation	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in programmed necrotic cell death	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial outer membrane permeabilization involved in programmed cell death	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of oxidative phosphorylation uncoupler activity	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein kinase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
apoptotic process	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
viral release from host cell	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neuron differentiation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neutrophil chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
leukocyte chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
activation of protein kinase B activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of stress-activated MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
lipid droplet organization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cellular response to oxidative stress	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein dephosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
endothelial cell activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein secretion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cell adhesion molecule production	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein K48-linked ubiquitination	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet aggregation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of viral life cycle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
collagen binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
unfolded protein binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
RNA polymerase binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
peptide binding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
integrin binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
virion binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
unfolded protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
heparan sulfate binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
nucleoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum lumen	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
smooth endoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
focal adhesion	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
melanosome	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
perinuclear region of cytoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum chaperone complex	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
intracellular membrane-bounded organelle	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
mitochondrial proton-transporting ATP synthase complex	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrion	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial permeability transition pore complex	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrion	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
extracellular region	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular space	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
focal adhesion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
vesicle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
secretory granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
ficolin-1-rich granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (148)

Assay ID	Title	Year	Journal	Article
AID1178324	Antiviral activity against HIV1 in HCV and HIV co-infected human patient assessed as log reduction in plasma HIV1 RNA dosed for 10 days	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
AID573111	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID581926	Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555925	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID555936	Cytotoxicity against human Huh-9-13 cells at 5 ug/ml after 3 days by MTT assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1168840	Cytotoxicity against PHA-stimulated human PBMC by 5-bromo-2'-deoxyuridine incorporation assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID573107	Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID581785	Antiviral activity against HIV1 subtype A 92RW016 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581958	Cytotoxicity against human HepAD38 cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168850	AUC in dog plasma at 1 mg/kg, po after 72 hrs	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581800	Antiviral activity against HIV1 subtype F 93BR020 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581953	Antiviral activity against HPV-33 infected in CK1 cells assessed as inhibition of viral replication after 7 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581914	Antiviral activity against LPV, APV, ATV, IDV, NFV, RTV, SQV-resistant HIV-1 52-52 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID573106	Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID581945	Antiviral activity against Human cytomegalovirus Davis infected in human embryonic lung cells assessed as reduction in viral yield	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581915	Antiviral activity against Simian immunodeficiency virus-mac 251 infected in human PBMC assessed as inhibition of viral replication by RT activity	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168844	Inhibition of BSEP (unknown origin) expressed in HEK293 cells using [3H]taurocholic acid substrate	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID555927	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 1 passages at 5 ug/ml by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581921	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581767	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as IgM level at 10 mg/kg, po administered once daily for 28 days by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581929	Cytotoxicity against human embryonic lung cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168845	Inhibition of BCRP (unknown origin) expressed in T8 cells using Bodipy FL-prazosin substrate	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID1714205	Inhibition of NS5A L31V mutant in HCV genotype 1b infected in HuH7.5Lcu-Neo cells assessed as reduction in viral replication by luciferase reporter gene assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID581784	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent cytotoxic T cells at 50 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555932	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 3 passages at 1 ug/ml by quantitative RT-PCR in presence of G418 selection pressure	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID762651	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 to 6 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Cyclophilin inhibitors as antiviral agents.
AID1168834	Dissociation constant, basic pKa of the compound	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID1168849	AUC in dog blood at 1 mg/kg, po after 72 hrs	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581955	Antiviral activity against HIV-1 NL4-3 infected in human TZB cells assessed as inhibition of accumulation of late viral transcripts at 0.5 to 2.5 uM by RT-PCR	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581916	Antiviral activity against Simian immunodeficiency virus PBj infected in human PBMC assessed as inhibition of viral replication by RT activity	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1714207	Inhibition of NS5A in HCV genotype 1b infected in HuH7.5Lcu-Neo cells assessed as reduction in viral replication by luciferase reporter gene assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID581950	Antiviral activity against HPV-33 infected in CK1 cells assessed as inhibition of viral replication after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581913	Antiviral activity against APV, ATV, IDV, LPV, NFV, RTV, SQV, AZT, ddI, 3TC, d4T-resistant HIV-1 MDR1385 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581803	Antiviral activity against LPV, APV, ATV, IDV, NFV, RTV, SQV, AZT, ddI, 3TC, d4T-resistant HIV-1 MDR3761 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168837	Antiviral activity against HCV subtype 1a in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581798	Antiviral activity against HIV1 subtype EA CMU02 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581933	Antiviral activity against HCV infected in human Huh 5.2 cells assessed as reduction in viral RNA level by luciferase reporter gene assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581951	Antiviral activity against HPV-16 infected in Caski cells assessed as inhibition of viral replication after 7 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581791	Antiviral activity against HIV1 subtype B 92BR014 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555950	Antiviral activity against compound-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1168835	Binding affinity to human cyclophilin B by surface plasmon resonance method	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581944	Antiviral activity against Human cytomegalovirus AD169 infected in human embryonic lung cells assessed as reduction in viral yield	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555953	Antiviral activity against R479-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID555929	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 2 passages at 1 ug/ml by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581924	Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581804	Antiviral activity against ABC, ddC, ddI, TDF, AZT, d4T-resistant HIV-1 G910-6 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581762	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T lymphocytes at 25 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581920	Cytotoxicity against african green monkey Vero cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168847	AUC in rat blood at 25 mg/kg, po after 72 hrs	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID1168846	Inhibition of MDR1 (unknown origin) expressed in MDA T0.3 cells using rhodamine 123 substrate	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581786	Antiviral activity against HIV1 subtype A 92UG037 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581774	Antiviral activity against HIV-1 SF2 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581923	Cytotoxicity against MDCK cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID573109	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1168839	Cytotoxicity against human MT4 cells by CDCF probe based assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID1168836	Binding affinity to human cyclophilin F by surface plasmon resonance method	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581801	Antiviral activity against HIV1 subtype O BCF01 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168848	AUC in rat plasma at 25 mg/kg, po after 72 hrs	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID573110	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1168841	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using [3H]estradiol-17beta-glucuronide substrate	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581796	Antiviral activity against HIV1 subtype C 92BR025 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555939	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 8 passages at 0.25 ug/ml by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581942	Antiviral activity against Herpes simplex virus 2 Lyons infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581938	Antiviral activity against Herpes simplex virus 1 F infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581919	Antiviral activity against Coxsackie B3 infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581934	Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581941	Antiviral activity against Herpes simplex virus 2 196 infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1714203	Inhibition of NS5B S282T mutant in HCV genotype 1b infected in HuH7.5Lcu-Neo cells assessed as reduction in viral replication by luciferase reporter gene assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID719606	Binding affinity to human cyclophilin A by fluorescence polarization assay	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Ranking high affinity ligands of low solubility by NMR spectroscopy.
AID581939	Antiviral activity against Herpes simplex virus 1 McIntyre infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581799	Antiviral activity against HIV1 subtype G Jv1083 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID762647	Antiviral activity against Hepatitis C virus infected in human HuH5.2 cells after 72 hrs by luciferase reporter gene assay	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Cyclophilin inhibitors as antiviral agents.
AID581927	Cytotoxicity against human HeLa cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581792	Antiviral activity against HIV1 subtype B SLKA infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581787	Antiviral activity against HIV1 subtype B NL4-3 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581937	Antiviral activity against Herpes simplex virus 1 KOS infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581775	Antiviral activity against HIV-1 NL4-3 infected in human TZB cells assessed as inhibitory effect on the completion of viral double stranded DNA at 0.5 to 2.5 uM by RT-PCR	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581928	Antiviral activity against VSV infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555952	Antiviral activity against 2'-C-methyl-2'-fluoro-cytidine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID573105	Cytotoxicity against human HuH6 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID581782	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent cytotoxic T cells at 10 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581765	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as IgM level at 25 mg/kg, po administered once daily for 28 days by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581776	Antiviral activity against HIV-1 3B infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168842	Inhibition of OATP1B3 (unknown origin) expressed in HEK293 cells using [3H]estradiol-17beta-glucuronide substrate	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581947	Antiviral activity against Vaccinia virus infected in human embryonic lung cells assessed as reduction in viral yield measured after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581790	Antiviral activity against HIV1 subtype B Ba-L infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581778	Inhibition of human recombinant cyclophilin-associted cis-trans propyl isomerase activity	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168825	Antiviral activity against HCV subtype 1b in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID555938	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 7 passages at 0.25 ug/ml by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581793	Antiviral activity against HIV1 subtype B TEKI infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581932	Cytotoxicity against CRFK	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168826	Inhibition of OATP1B1 (unknown origin) expressed in CHO cells using 8-fluorescein-cAMP substrate by fluorescent photometry	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID555935	Cytotoxicity against human Huh-9-13 cells at 1 ug/ml after 3 days by MTT assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581777	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1714206	Inhibition of NS5A D320E/Y321N mutant in HCV genotype 1b infected in HuH7.5Lcu-Neo cells assessed as reduction in viral replication by luciferase reporter gene assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID581940	Antiviral activity against Herpes simplex virus 2 G infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581771	Cytotoxicity against human MT4 cells at 0.83 uM by MTT assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555937	Cytotoxicity against human Huh-9-13 cells at 30 ug/ml after 3 days by MTT assay	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID555928	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 2 passages at 5 ug/ml by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581931	Antiviral activity against Feline coronavirus infected in CRFK assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581917	Antiviral activity against HIV-2 isolate CDC310342 infected in human PBMC assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555955	Antiviral activity against VX 950-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581948	Antiviral activity against HPV-16 infected in Caski cells assessed as inhibition of viral replication after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581797	Antiviral activity against HIV1 subtype D 92UG046 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581783	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent cytotoxic T cells at 25 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID573112	Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID581763	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T lymphocytes at 10 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168827	Kinetic solubility of the compound in pH 7.0 water	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581795	Antiviral activity against HIV1 subtype B WEJO infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581930	Antiviral activity against SARS coronavirus infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1178323	Antiviral activity against HCV in HCV and HIV co-infected human patient assessed as log reduction in plasma HCV RNA dosed for 10 days	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
AID581788	Antiviral activity against HIV1 subtype B JR-CSF infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168843	Inhibition of human MRP2 expressed in Sf9 cells inside out vesicles using CDCF substrate	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581922	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID573108	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1168824	Binding affinity to human cyclophilin A by surface plasmon resonance method	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581952	Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 7 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581789	Antiviral activity against HIV1 subtype B SF162 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581768	Antiproliferative activity against mouse PBMC with MLR assessed as inhibition of [3H]thymidine incorporation after 18 hrs	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581925	Antiviral activity against Parainfluenza 3 infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555954	Antiviral activity against BILN 2061-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581943	Antiviral activity against VZV OKA infected in human embryonic lung cells assessed as inhibition of	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555926	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 1 passages at 0.82 uM by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1714204	Inhibition of NS3 R155Q/A156T mutant in HCV genotype 1b infected in HuH7.5Lcu-Neo cells assessed as reduction in viral replication by luciferase reporter gene assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID719605	Binding affinity to human cyclophilin A assessed as compound-enzyme complex formation at 1:1 protein to compound ratio by NMR analysis	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Ranking high affinity ligands of low solubility by NMR spectroscopy.
AID581949	Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581764	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as IgM level at 50 mg/kg, po administered once daily for 28 days by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555934	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 7 passages at 30 ug/ml by quantitative RT-PCR in presence of G418 selection pressure	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID555933	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 7 passages at 5 ug/ml by quantitative RT-PCR in presence of G418 selection pressure	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581954	Antiviral activity against HIV-1 NL4-3 infected in human TZB cells assessed as inhibition of accumulation of early viral transcripts at 0.5 to 2.5 uM by RT-PCR	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581918	Antiviral activity against HIV-2 isolate CDC310319 infected in human PBMC assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168833	Lipophilicity, log D of the compound	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581935	Antiviral activity against Yellow fever virus 17D infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581779	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T-helper cells at 10 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581957	Antiviral activity against HIV-1 NL4-3 cells infected in human TZB cells assessed as degradation of cDNA at 0.5 to 2.5 uM after 6 hrs postinfection by RT-PCR	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581761	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T lymphocytes at 50 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1168838	Antiviral activity against HCV subtype 1b in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene in presence of 40% human serum	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID581770	Cytotoxicity against human PBMC at 0.83 uM by MTT assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581802	Antiviral activity against APV, ATV, LPV, IDV, NFV, RTV, SQV-resistant HIV-1 1064-52 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581794	Antiviral activity against HIV1 subtype B ROJO infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID555951	Antiviral activity against cyclosporine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID581946	Antiviral activity against HBV infected in human hepAD38 cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581781	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T-helper cells at 50 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581780	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T-helper cells at 25 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581773	Immunosuppressive activity in human Jurkat cells assessed as inhibition of PHA-phorbol myristate acetate induced beta-galactosidase activity at 21.5 uM	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581956	Antiviral activity against HIV-1 NL4-3 infected in human TZB cells assessed as inhibition of viral entry at 0.5 to 2.5 uM after 2 hrs by RT-PCR	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581936	Cytotoxicity against human Huh 5.2 cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID581805	Antiviral activity against APV, ATV, IDV, LPV, NFV, RTV, SQV, 3TC, FTC, ABC, AZT, d4T, ddC, ddI, TDF, EFV, DLV, NVP-resistant HIV-1 MDR769 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (20.99)	29.6817
2010's	52 (64.20)	24.3611
2020's	12 (14.81)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (11.11%)	5.53%
Reviews	13 (16.05%)	6.00%
Case Studies	1 (1.23%)	4.05%
Observational	0 (0.00%)	0.25%
Other	58 (71.60%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carbamates [no description available]	4.71	3	0	amino-acid anion
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	2.04	1	0
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.05	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.89	2	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	3.16	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.05	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
uridine monophosphate Uridine Monophosphate: 5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. uridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having uracil as the nucleobase.	3.17	1	0	pyrimidine ribonucleoside 5'-monophosphate; uridine 5'-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.05	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	4.93	4	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	3.23	1	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	3.16	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiophene-2-carboxylate thiophene-2-carboxylic acid : A thiophenecarboxylic acid in which the carboxy group is located at position 2.	2.04	1	0	thiophenecarboxylic acid
deoxycytidine [no description available]	3.16	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.31	1	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.04	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ribavirin Rebetron: Rebetron is tradename	9.59	9	4	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.16	1	0	benzamides; carboxylic ester
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	7.41	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.1	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	3.5	1	1	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
4'-azidocytidine 4'-azidocytidine: antiviral; structure in first source	2.45	2	0	N-glycosyl compound
2'-c-methyladenosine 2'-C-methyladenosine: antiviral	2.04	1	0
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.45	2	0
telaprevir [no description available]	2.99	4	0	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
plaunotol plaunotol: RN refers to (Z,E,E)-isomer. plaunotol : A diterpenoid that is geranylgeraniol carrying an additional hydroxy substituent at position 18.	3.16	1	0	diterpenoid; primary alcohol	anti-ulcer drug; antibacterial agent; antineoplastic agent; apoptosis inducer; nephroprotective agent; plant metabolite; vulnerary
geranylgeranylacetone geranylgeranylacetone: structure in first source; RN given refers to isomeric cpd without isomeric designation; mixture of (5E,9E,13E) & (5Z,9E,13E)-isomers. teprenone : A terpene ketone in which a (9E,13E)-geranylgernayl group is bonded to one of the alpha-methyls of acetone (it is a mixture of 5E- and 5Z-geoisomers in a 3:2 ratio).	3.16	1	0
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	3.31	6	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
sanglifehrin a sanglifehrin A: binds cyclophilin A; isolated from Streptomyces; structure in first source	2.8	3	0
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid Fluvastatin: An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.. (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which both chiral centres have S configuration.. fluvastatin : A racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. An HMG-CoA reductase inhibitor, it is used (often as the corresponding sodium salt) to reduce triglycerides and LDL-cholesterol, and increase HDL-chloesterol, in the treatment of hyperlipidaemia.	3.16	1	0	(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
n-methyl-valyl-4-cyclosporin a N-methyl-valyl-4-cyclosporin A: a cyclosporin A analog	2.08	1	0
(melle-4)cyclosporin (melle-4)cyclosporin: a non-immunosuppressive analog of cyclosporin A	6.14	12	0
scy-635 [no description available]	4.94	6	0
cajanine cajanine: isolated from Cajanus cajan L.; structure in first source	2.13	1	0	stilbenoid
biln 2061 BILN 2061: a macrocyclic NS3 protease inhibitor and antiviral agent; structure in first source	2.45	2	0
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	2.04	1	0	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
cyclosporine metabolite m17 cyclosporin A metabolite M17 : A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol. It specifically inhibits growth of renal cells in culture.	2.08	1	0	cyclosporin A derivative; primary allylic alcohol	drug metabolite
mitoquinone mitoquinone: has antineoplastic activity	3.19	1	0
hcv 796 HCV 796: inhibits HCV RdRp; structure in first source	2.04	1	0
rg 7128 2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine: inhibits HCV polymerase; structure in first source	3.16	1	0
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	3.19	1	0
amorfrutin a amorfrutin A: an antidiabetic agent that inhibits NF-kappaB activation; structure in first source	2.13	1	0	stilbenoid
simeprevir [no description available]	2.13	1	0	azamacrocycle; lactam
bms-790052 daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.	4.95	4	0	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor
sofosbuvir Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	3.9	3	0	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug
ledipasvir ledipasvir : A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	3.19	1	0	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor
tro 40303 3,5-seco-4-norcholestan-5-one oxime-3-ol: a cardioprotective agent; structure in first source	4.13	2	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	19.68	77	9
silybin Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.	3.16	1	0
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.89	2	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Indicated	Relationship Strength	Studies	Trials
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	0	10.76	19	3
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	1	12.76	19	3
Becker Muscular Dystrophy [description not available]	0	3.06	4	0
Muscular Dystrophy, Duchenne An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)	0	3.06	4	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	0	2.41	1	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	0	7.41	1	0
Infections, Plasmodium [description not available]	0	2.41	1	0
Plasmodium falciparum Malaria [description not available]	0	2.41	1	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	0	7.41	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	2.41	1	0
Alloxan Diabetes [description not available]	0	2.25	1	0
Diabetic Glomerulosclerosis [description not available]	0	2.25	1	0
Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES.	0	2.25	1	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	0	2.25	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	2.25	1	0
Infections, Coronavirus [description not available]	0	3.82	3	0
2019 Novel Coronavirus Disease [description not available]	0	3.57	2	0
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	0	3.17	1	0
Coronavirus Infections Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).	0	3.82	3	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	4.73	10	0
Cognitive Decline [description not available]	0	2.31	1	0
Acute Confusional Senile Dementia [description not available]	0	2.72	2	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.72	2	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	0	2.31	1	0
Muscular Dystrophy, Animal MUSCULAR DYSTROPHY that occurs in VERTEBRATE animals.	0	2.98	4	0
Chronic Hepatitis C [description not available]	0	14.86	13	5
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	1	11.86	13	5
HIV Coinfection [description not available]	0	5.05	3	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	0	5.05	3	1
Muscular Dystrophy [description not available]	0	2.46	2	0
Muscular Dystrophies A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS.	0	2.46	2	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	3.01	1	0
Adverse Drug Event [description not available]	0	3.5	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	3.5	1	1
Diabetes Mellitus, Adult-Onset [description not available]	0	2.11	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	0	2.11	1	0
Ebola Hemorrhagic Fever [description not available]	0	2.13	1	0
Hemorrhagic Fever, Ebola A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS.	0	2.13	1	0
Respiratory Syndrome, Acute, Severe [description not available]	0	2.15	1	0
Severe Acute Respiratory Syndrome A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.	1	4.15	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	2.44	2	0
Muscle Disorders [description not available]	0	2.05	1	0
Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.	0	2.05	1	0
Intestinal Diseases Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.	0	2.05	1	0
Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.	0	2.05	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.07	1	0
Left Ventricular Dysfunction [description not available]	0	2.03	1	0
Cardiovascular Stroke [description not available]	0	2.03	1	0
Injury, Ischemia-Reperfusion [description not available]	0	2.03	1	0
Acute Disease Disease having a short and relatively severe course.	0	2.03	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	2.03	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	2.03	1	0
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	0	2.03	1	0

alisporivir

Description

Cross-References

Synonyms (39)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (11)

Inhibition Measurements

Activation Measurements

Biological Processes (108)

Molecular Functions (43)

Ceullar Components (39)

Bioassays (148)

Research

Studies (81)

Market Indicators

Research Demand Index: 29.41

Study Types

alisporivir

Description

Cross-References

Synonyms (39)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (11)

Inhibition Measurements

Activation Measurements

Biological Processes (108)

Molecular Functions (43)

Ceullar Components (39)

Bioassays (148)

Research

Studies (81)

Market Indicators

Research Demand Index: 29.41

Study Types

Related Drugs (49)

Related Conditions (53)